Breast Cancer Research Updates

Weekly updates on the most current research in breast cancer.

Will follow all cancer researchers back.

Here to make research more available to everyone.

[Breast Cancer Research Updates @BreastCaupdates]

If you are a young breast cancer researcher who would like to be featured on our wall please send a DM 🩺

#breastcancer #youngresearchers #youngoncologists #research #cancer #oncology #epitwitter #phdchat #PhD #cancerresearch #younginvestigator #globaloncology

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Top #ASCO24 picks in breast #bcsm oncology!

Exciting! Next week!

@OncoAlert
@SarahCannonDocs
@myESMO

[Kevin Punie @kevinpunie]

#ESMOBreast24 #ESMOAmbassadors
🔑🚫Primary outcome in IMpassion132 highlights unmet need for early relapsing #TNBC
🔑Emerging data from ADC-IO combinations
🔑Safety and #QoL updates for new 💊capivasertib and 💉datopotamab
🔑📈Body of evidence for new biomarkers 🎯such as HER2Dx

[Dr. Iván R. González @Dr_Ivanoncologo]

A very interesting review🙌🏻😱 on the complex relationship between diabetes and breast cancer raises crucial considerations in treatment decisions, especially in women with comorbidities. The review 🕵🏻highlights the undeniable connection between diabetes and an increased risk of developing breast cancer, underlining the importance of careful management of anti-diabetic therapy.
🟩The promising effects observed in new antidiabetic drugs are explored, suggesting potential benefits in reducing cancer risk. The research also hints at the relevance of reconsidering current recommendations for the pharmacological prevention of breast cancer, especially in individuals with overweight or type 2 diabetes.
🟦Precise management of therapies such as insulin, metformin, and SGLT-2 inhibitors emerges as a determining factor that could positively impact prognosis. These new anti-diabetic drugs generate hope by offering innovative strategies for cancer risk reduction.
🟧Taken together, it is suggested that comprehensive diabetes management in breast cancer patients may have a significant impact on prognosis. 💡The possibility of adjusting pharmacological preventive strategies is proposed as a way to optimize outcomes in patients with these concomitant conditions. @OncoReporte @VukovicPetra @Dr_RShatsky @AnaVManana
https://t.co/JZzuHujdG0

[Xia & He Publishing @xiahepublishing]

📈 Highly cited paper (2022): "Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice" by Dr. @SeanHacking and Dr. Yihong Wang (@BrownPathRes @BrownPathology).

🔗 Read more: https://t.co/Dqhs0FY47o

👥 @CAPA_comm @gcai1978 @BreastCaupdates @ElisaAgostinett

[Breast Cancer Research Updates @BreastCaupdates]

UPDATE ALERT‼️

Read!👇

[Dr. Iván R. González @Dr_Ivanoncologo]

Great news‼️🚨 Updates to germline testing in #breastcancer patients from @ASCO and the Society of Surgical Oncology emphasize the paramount importance of BRCA1/2 mutation testing in newly diagnosed breast cancer patients, especially those ≤65 years of age, and in patients over 65 years of age, taking into account their personal history, relatives, ancestry, and eligibility for poly(ADP-ribose) polymerase inhibitor (PARP) therapy.
Recommendations:
🔵All newly diagnosed breast cancer patients ≤65 years of age should undergo BRCA1/2 mutation testing.
🟣Selected patients over 65 years of age should be evaluated based on history, ancestry, and eligibility for PARP therapy.
🟡Patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should undergo the BRCA1/2 test, regardless of family history.
🟠Women with second primary cancer in the ipsilateral or contralateral breast should undergo BRCA1/2 testing.
🟢Patients with a history of breast cancer, without active disease, should be evaluated, selectively, according to age of diagnosis and personal and family risk.
🌟Expansion of testing to high-penetrance cancer susceptibility genes beyond BRCA1/2 is also recommended, especially in those with a supportive family history. Where necessary, moderate-penetrance gene testing may be offered to assess personal and family cancer risk, this comprehensive approach makes a huge difference in personalizing breast cancer therapy and prevention.🙌🏻 @OncoReporte @oncosurgeonjd @Dr_RShatsky @ProfAMThompson
https://t.co/rMtdYBxwds

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New @JCO_ASCO🗞️| RCT of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With #BreastCancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.
@tarasanftmd #JenniferLigibel @DrDawnHershman
👉https://t.co/WgrRmg7e3r

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

🚨After Neoadj chemo for cT1-2N0-1M0 TNBC or HER2+ BC, this trial used core biopsy to confirm pCR. Pts were then tx w/ RT alone WITHOUT breast surgery
Biopsy=pCR in 31/50 patients
‼️3-year ipsilateral breast tumour recurrence (IBTR) rate = 0% and 3-yr DFS and OS =100% #ESMO23

[Sara Tolaney @stolaney1]

BEGONIA: Dato-DXd + Durvalumab in mTNBC update

ORR 79%
mPFS 13.8 mo
>80% with low PDL1 expression (by SP263 or 22C3)

Can IO lead to benefit even in PDL1- tumors when combined with a potent ADC?

#ESMO23 @OncoAlert #bcsm

[Breast Cancer Research Updates @BreastCaupdates]

@Dr_LEMcCullough 👏🏻

[Lauren E. McCullough @Dr_LEMcCullough]

Excited to share this paper that discusses priorities to reducing race disparities in breast cancer. Grateful to @maretmaliniak and @LMoubadder for their support of this idea and contributions to the content. @WinshipAtEmory @EmoryRollins
https://t.co/s8HGc5yI9s

[Breast Cancer Research Updates @BreastCaupdates]

UPDATE ‼️

[Sara Tolaney @stolaney1]

TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo

63% w/1L prior chemo
~80% w/prior cdk 4/6i

PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001
ORR 36.4% vs 22.9%

Fewer grade >=3 AEs w/Dato-DXd c/w TPC
50% Stomatitis,3% ILD

@OncoAlert #bcsm #ESMO23 @dradityabardia

[OncLive.com @OncLive]

⭐️Dr. Paolo Tarantino discusses the large improvement in pathological complete response w/chemo immunotherapy for high risk HR+ Stage 2/3 breast cancer. We also talk about the use of CDK4 inhibitor and PD inhibitor after surgery. #ESMO23 @CParkMD #OncLiveTakeOver
@PTarantinoMD

[Breast Cancer Research Updates @BreastCaupdates]

UPDATE - OBESITY & BREAST CANCER RECURRENCE‼️

This study suggests that obesity is associated with an increased risk of recurrence among patients with hormone receptor–positive breast cancer treated with aromatase inhibitors‼️

https://t.co/R4V4wgLLjT

[Breast Cancer Research Updates @BreastCaupdates]

UPDATE‼️
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial | Journal of Clinical Oncology ‼️ https://t.co/foxlxooVWz

[HemOnc Today @HemOncToday]

Healio spoke with @AnnPartridgeMD in this exclusive cover story regarding data that shows the overwhelming majority of new breast cancer diagnoses for women occur after the age of 40. Therefore, younger woman are underrepresented in clinical trials.
https://t.co/DkAO0xQRh8

[Breast Cancer Research Updates @BreastCaupdates]

Drug repurposing is great. The results from the MA.32 trial should discourage further investigation of metformin as an addition to adjuvant treatment of breast cancer patients…🛑

#bcsm

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Another study showing metformin doesn't have the effect on improving risk or outcome for #bcsm that we hoped it might.

@ASCO
#MA32

https://t.co/7xRz1RLF3N

[Paolo Tarantino @PTarantinoMD]

The longest follow up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study was still alive. https://t.co/QBYseKmqmL

How to recognize & increase the rate of long-term survivors? 👉 https://t.co/jJGW8BD36x

[#TumorBoardTuesday @TumorBoardTues]

Mark your calendar to join this #BCSM #TumorBoardTuesday 👆🏽

@DrSGraff @matteolambe @itrisabel @dr_yakupergun @NagiSaghir @YAbdouMD @BiagioRicciutMD @maryam_lustberg @DrEricWiner @AnselmoBertetti @anelcabrera @dsmithgraz @stolaney1 @DenizCanGuven1 @dralanreyesonco @HaanenJohn @ErikaHamilton9 @JAMouabbi @MartaPerachino @FuenteApolo @breastDoktor @amybeumer @oncologician @AnisToumeh @Icro_Meattini @DrJuliaKennedy1 @benjiwal @EMariamidze @GlopesMd @Dr_Ivanoncologo @WinshipAtEmory @OhioStateMedOnc

[#TumorBoardTuesday @TumorBoardTues]

🍂@jane_meisel @quirogad are finalizing the upcoming #BCSM #TumorBoardTuesday for 10/03

🌴Join at 8pm ET to discuss CDK4/6i treatment options & breaking updates to ADC use in those with HR+/HER2- met #BreastCancer

🏝️FREE #CME
👉🏽https://t.co/Gzqzvik9BR👈🏼

[Breast Cancer Research Updates @BreastCaupdates]

Yeees❗️

Put this in your calendar 📅

Make sure to keep yourself updated‼️

[Deniz Can Guven @DenizCanGuven1]

Expect a great discussion and update on HR+ breast cancer 🧬🧬

@matteolambe @dr_yakupergun @ErikaHamilton9 @quirogad @BreastCaupdates @oncodaily @BreastAdvocate @Erman_Akkus

[Breast Cancer Research Updates @BreastCaupdates]

UPDATE FROM MA.32 trial ‼️

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer | Journal of Clinical Oncology https://t.co/v1Klr0avKd